

# Accepted Manuscript

## Imidazole - Derived Agonists for the Neurotensin 1 Receptor

Paul M. Hershberger, Michael P. Hedrick, Satyamaheshwar Peddibhotla, Arianna Mangravita-Novo, Palak Gosalia, Yujie Li, Wilson Gray, Michael Vicchiarelli, Layton H. Smith, Thomas D.Y. Chung, James B. Thomas, Marc G. Caron, Anthony B. Pinkerton, Lawrence S. Barak, Gregory P. Roth


PII: S0960-894X(13)01305-X  
DOI: <http://dx.doi.org/10.1016/j.bmcl.2013.11.026>  
Reference: BMCL 21053

To appear in: *Bioorganic & Medicinal Chemistry Letters*

Received Date: 2 October 2013  
Revised Date: 6 November 2013  
Accepted Date: 11 November 2013

Please cite this article as: Hershberger, P.M., Hedrick, M.P., Peddibhotla, S., Mangravita-Novo, A., Gosalia, P., Li, Y., Gray, W., Vicchiarelli, M., Smith, L.H., Chung, T.D.Y., Thomas, J.B., Caron, M.G., Pinkerton, A.B., Barak, L.S., Roth, G.P., Imidazole - Derived Agonists for the Neurotensin 1 Receptor, *Bioorganic & Medicinal Chemistry Letters* (2013), doi: <http://dx.doi.org/10.1016/j.bmcl.2013.11.026>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**Imidazole - Derived Agonists for the Neurotensin 1 Receptor**

Paul M. Hershberger<sup>\*, a</sup>, Michael P. Hedrick<sup>b</sup>, Satyamaheshwar Peddibhotla<sup>a</sup>, Arianna Mangravita-Novo<sup>a</sup>, Palak Gosalia, Yujie Li, Wilson Gray, Michael Vicchiarelli<sup>a</sup>, Layton H. Smith<sup>a</sup>, Thomas D.Y. Chung<sup>b</sup>, James B. Thomas<sup>d</sup>, Marc G. Caron<sup>c</sup>, Anthony B. Pinkerton<sup>b</sup>, Lawrence S. Barak<sup>c</sup>, Gregory P. Roth<sup>a</sup>

<sup>a</sup>Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, Florida 32827, USA, <sup>b</sup>Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, USA and <sup>c</sup>Duke University Medical Center, Durham, NC 27710, USA, RTI International, 3040 E Cornwallis Road, Durham, North Carolina 27709, United States.

This is where the receipt/accepted dates will go; Received Month XX, 2012; Accepted Month XX, 2013 [BMCL RECEIPT]

---

**Abstract**— A scaffold-hop program seeking full agonists of the neurotensin-1 (NTR1) receptor identified the probe molecule **ML301 (1)** and associated analogs, including its naphthyl analog (**14**) which exhibited similar properties. Compound **1** showed full agonist behavior (79 - 93%) with an EC<sub>50</sub> of 2.0 – 4.1  $\mu$ M against NTR1. Compound **1** also showed good activity in a Ca mobilization FLIPR assay (93% efficacy at 298 nM), consistent with it functioning via the G<sub>q</sub> coupled pathway, and good selectivity relative to NTR2 and GPR35. In further profiling, **1** showed low potential for promiscuity and good overall pharmacological data. This report describes the discovery, synthesis, and SAR of **1** and associated analogs. Initial *in vitro* pharmacologic characterization is also presented.

---

<sup>\*</sup>To whom correspondence should be addressed. Tel. +1-407-745-2000. E-mail: phershberger@sanfordburnham.org

Download English Version:

<https://daneshyari.com/en/article/10592822>

Download Persian Version:

<https://daneshyari.com/article/10592822>

[Daneshyari.com](https://daneshyari.com)